Denosumab: a novel antiresorptive drug for osteoporosis.

Abstract

Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.

• Authors: Ernest Suresh, Bo Abrahamsen
• Journal: Cleveland Clinic journal of medicine (Cleve Clin J Med) Vol. 82 Issue 2 Pg. 105-14 (Feb 2015) ISSN: 1939-2869 [Electronic] United States
• PMID: 25897599 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: Copyright © 2015 Cleveland Clinic.

Chemical References

• Antibodies, Monoclonal, Humanized
• Bone Density Conservation Agents
• RANK Ligand
• Denosumab

Topics

• Absorptiometry, Photon
• Aged
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bone Density (drug effects)
• Bone Density Conservation Agents (therapeutic use)
• Denosumab
• Female
• Humans
• Lumbar Vertebrae (injuries)
• Osteoporosis (complications, diagnostic imaging, drug therapy)
• Osteoporotic Fractures (diagnostic imaging, drug therapy, etiology)
• RANK Ligand (antagonists & inhibitors)
• Spinal Fractures (drug therapy, etiology)
• Thoracic Vertebrae (injuries)